Global API CDMO Services 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI03259532

Publication Date:

March 31, 2025

Pages:

137

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global API CDMO Services market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The 鈥淎PI CDMO Services Industry Forecast鈥� looks at past sales and reviews total world API CDMO Services sales in 2024, providing a comprehensive analysis by region and market sector of projected API CDMO Services sales for 2025 through 2031. With API CDMO Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world API CDMO Services industry.
This Insight Report provides a comprehensive analysis of the global API CDMO Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on API CDMO Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global API CDMO Services market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for API CDMO Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global API CDMO Services.
This report presents a comprehensive overview, market shares, and growth opportunities of API CDMO Services market by product type, application, key players and key regions and countries.
Segmentation by Type:
Traditional API CDMO
Highly Potent API CDMO
Segmentation by Application:
Pharmaceutical Company
Research Institute
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
EUROAPI
Cambrex
Recipharm
Thermo Fisher Scientific
CordenPharma
Samsung Biologics
Lonza
Catalent
Siegfried
PiramalPharma Solutions
Boehringer-Ingelheim
Wuxi Apptec
Pharmaron Beijing
Asymchem Laboratories (Tianjin)
Porton
SEQENS
Lebsa
Langhua Pharma

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global API CDMO Services 麻豆原创 Size (2020-2031)
2.1.2 API CDMO Services 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for API CDMO Services by Country/Region (2020, 2024 & 2031)
2.2 API CDMO Services Segment by Type
2.2.1 Traditional API CDMO
2.2.2 Highly Potent API CDMO
2.3 API CDMO Services 麻豆原创 Size by Type
2.3.1 API CDMO Services 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global API CDMO Services 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 API CDMO Services Segment by Application
2.4.1 Pharmaceutical Company
2.4.2 Research Institute
2.5 API CDMO Services 麻豆原创 Size by Application
2.5.1 API CDMO Services 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global API CDMO Services 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 API CDMO Services 麻豆原创 Size by Player
3.1 API CDMO Services 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global API CDMO Services Revenue by Player (2020-2025)
3.1.2 Global API CDMO Services Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global API CDMO Services Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 API CDMO Services by Region
4.1 API CDMO Services 麻豆原创 Size by Region (2020-2025)
4.2 Global API CDMO Services Annual Revenue by Country/Region (2020-2025)
4.3 Americas API CDMO Services 麻豆原创 Size Growth (2020-2025)
4.4 APAC API CDMO Services 麻豆原创 Size Growth (2020-2025)
4.5 Europe API CDMO Services 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa API CDMO Services 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas API CDMO Services 麻豆原创 Size by Country (2020-2025)
5.2 Americas API CDMO Services 麻豆原创 Size by Type (2020-2025)
5.3 Americas API CDMO Services 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC API CDMO Services 麻豆原创 Size by Region (2020-2025)
6.2 APAC API CDMO Services 麻豆原创 Size by Type (2020-2025)
6.3 APAC API CDMO Services 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe API CDMO Services 麻豆原创 Size by Country (2020-2025)
7.2 Europe API CDMO Services 麻豆原创 Size by Type (2020-2025)
7.3 Europe API CDMO Services 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa API CDMO Services by Region (2020-2025)
8.2 Middle East & Africa API CDMO Services 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa API CDMO Services 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global API CDMO Services 麻豆原创 Forecast
10.1 Global API CDMO Services Forecast by Region (2026-2031)
10.1.1 Global API CDMO Services Forecast by Region (2026-2031)
10.1.2 Americas API CDMO Services Forecast
10.1.3 APAC API CDMO Services Forecast
10.1.4 Europe API CDMO Services Forecast
10.1.5 Middle East & Africa API CDMO Services Forecast
10.2 Americas API CDMO Services Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 API CDMO Services Forecast
10.2.2 Canada 麻豆原创 API CDMO Services Forecast
10.2.3 Mexico 麻豆原创 API CDMO Services Forecast
10.2.4 Brazil 麻豆原创 API CDMO Services Forecast
10.3 APAC API CDMO Services Forecast by Region (2026-2031)
10.3.1 China API CDMO Services 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 API CDMO Services Forecast
10.3.3 Korea 麻豆原创 API CDMO Services Forecast
10.3.4 Southeast Asia 麻豆原创 API CDMO Services Forecast
10.3.5 India 麻豆原创 API CDMO Services Forecast
10.3.6 Australia 麻豆原创 API CDMO Services Forecast
10.4 Europe API CDMO Services Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 API CDMO Services Forecast
10.4.2 France 麻豆原创 API CDMO Services Forecast
10.4.3 UK 麻豆原创 API CDMO Services Forecast
10.4.4 Italy 麻豆原创 API CDMO Services Forecast
10.4.5 Russia 麻豆原创 API CDMO Services Forecast
10.5 Middle East & Africa API CDMO Services Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 API CDMO Services Forecast
10.5.2 South Africa 麻豆原创 API CDMO Services Forecast
10.5.3 Israel 麻豆原创 API CDMO Services Forecast
10.5.4 Turkey 麻豆原创 API CDMO Services Forecast
10.6 Global API CDMO Services Forecast by Type (2026-2031)
10.7 Global API CDMO Services Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 API CDMO Services Forecast
11 Key Players Analysis
11.1 EUROAPI
11.1.1 EUROAPI Company Information
11.1.2 EUROAPI API CDMO Services Product Offered
11.1.3 EUROAPI API CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 EUROAPI Main Business Overview
11.1.5 EUROAPI Latest Developments
11.2 Cambrex
11.2.1 Cambrex Company Information
11.2.2 Cambrex API CDMO Services Product Offered
11.2.3 Cambrex API CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Cambrex Main Business Overview
11.2.5 Cambrex Latest Developments
11.3 Recipharm
11.3.1 Recipharm Company Information
11.3.2 Recipharm API CDMO Services Product Offered
11.3.3 Recipharm API CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Recipharm Main Business Overview
11.3.5 Recipharm Latest Developments
11.4 Thermo Fisher Scientific
11.4.1 Thermo Fisher Scientific Company Information
11.4.2 Thermo Fisher Scientific API CDMO Services Product Offered
11.4.3 Thermo Fisher Scientific API CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Thermo Fisher Scientific Main Business Overview
11.4.5 Thermo Fisher Scientific Latest Developments
11.5 CordenPharma
11.5.1 CordenPharma Company Information
11.5.2 CordenPharma API CDMO Services Product Offered
11.5.3 CordenPharma API CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 CordenPharma Main Business Overview
11.5.5 CordenPharma Latest Developments
11.6 Samsung Biologics
11.6.1 Samsung Biologics Company Information
11.6.2 Samsung Biologics API CDMO Services Product Offered
11.6.3 Samsung Biologics API CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Samsung Biologics Main Business Overview
11.6.5 Samsung Biologics Latest Developments
11.7 Lonza
11.7.1 Lonza Company Information
11.7.2 Lonza API CDMO Services Product Offered
11.7.3 Lonza API CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Lonza Main Business Overview
11.7.5 Lonza Latest Developments
11.8 Catalent
11.8.1 Catalent Company Information
11.8.2 Catalent API CDMO Services Product Offered
11.8.3 Catalent API CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Catalent Main Business Overview
11.8.5 Catalent Latest Developments
11.9 Siegfried
11.9.1 Siegfried Company Information
11.9.2 Siegfried API CDMO Services Product Offered
11.9.3 Siegfried API CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Siegfried Main Business Overview
11.9.5 Siegfried Latest Developments
11.10 PiramalPharma Solutions
11.10.1 PiramalPharma Solutions Company Information
11.10.2 PiramalPharma Solutions API CDMO Services Product Offered
11.10.3 PiramalPharma Solutions API CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 PiramalPharma Solutions Main Business Overview
11.10.5 PiramalPharma Solutions Latest Developments
11.11 Boehringer-Ingelheim
11.11.1 Boehringer-Ingelheim Company Information
11.11.2 Boehringer-Ingelheim API CDMO Services Product Offered
11.11.3 Boehringer-Ingelheim API CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Boehringer-Ingelheim Main Business Overview
11.11.5 Boehringer-Ingelheim Latest Developments
11.12 Wuxi Apptec
11.12.1 Wuxi Apptec Company Information
11.12.2 Wuxi Apptec API CDMO Services Product Offered
11.12.3 Wuxi Apptec API CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Wuxi Apptec Main Business Overview
11.12.5 Wuxi Apptec Latest Developments
11.13 Pharmaron Beijing
11.13.1 Pharmaron Beijing Company Information
11.13.2 Pharmaron Beijing API CDMO Services Product Offered
11.13.3 Pharmaron Beijing API CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Pharmaron Beijing Main Business Overview
11.13.5 Pharmaron Beijing Latest Developments
11.14 Asymchem Laboratories (Tianjin)
11.14.1 Asymchem Laboratories (Tianjin) Company Information
11.14.2 Asymchem Laboratories (Tianjin) API CDMO Services Product Offered
11.14.3 Asymchem Laboratories (Tianjin) API CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Asymchem Laboratories (Tianjin) Main Business Overview
11.14.5 Asymchem Laboratories (Tianjin) Latest Developments
11.15 Porton
11.15.1 Porton Company Information
11.15.2 Porton API CDMO Services Product Offered
11.15.3 Porton API CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 Porton Main Business Overview
11.15.5 Porton Latest Developments
11.16 SEQENS
11.16.1 SEQENS Company Information
11.16.2 SEQENS API CDMO Services Product Offered
11.16.3 SEQENS API CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.16.4 SEQENS Main Business Overview
11.16.5 SEQENS Latest Developments
11.17 Lebsa
11.17.1 Lebsa Company Information
11.17.2 Lebsa API CDMO Services Product Offered
11.17.3 Lebsa API CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.17.4 Lebsa Main Business Overview
11.17.5 Lebsa Latest Developments
11.18 Langhua Pharma
11.18.1 Langhua Pharma Company Information
11.18.2 Langhua Pharma API CDMO Services Product Offered
11.18.3 Langhua Pharma API CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.18.4 Langhua Pharma Main Business Overview
11.18.5 Langhua Pharma Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.